The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Trial of Deferiprone in Parkinson’s Disease
Open accessAbstract
BACKGROUND: Iron content is increased in the substantia nigra of persons with Parkinson's disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson's disease, but its effects on disease progression are unclear. METHODS: We conducted a multicenter, phase 2, randomized, double-blind trial involving participants with newly diagnosed Parkinson's disease who had never received levodopa. Participants were assigned (in a 1:1 ratio) to receive oral deferiprone at a dose of 15 mg per kilogram of body weight twice daily or matched placebo for 36 weeks. Dopaminergic therapy was withheld unless deemed necessary for symptom control. The primary outcome was the change in the total score on the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS; range, 0 to 260, with higher scores indicating more severe impairment) at 36 weeks. Secondary and exploratory clinical outcomes at up to 40 weeks included measures of motor and nonmotor disability. Brain iron content measured with the use of magnetic resonance imaging was also an exploratory outcome. RESULTS: A total of 372 participants were enrolled; 186 were assigned to receive deferiprone and 186 to receive placebo. Progression of symptoms led to the initiation of dopaminergic therapy in 22.0% of the participants in the deferiprone group and 2.7% of those in the placebo group. The mean MDS-UPDRS total score at baseline was 34.3 in the deferiprone group and 33.2 in the placebo group and increased (worsened) by 15.6 points and 6.3 points, respectively (difference, 9.3 points; 95% confidence interval, 6.3 to 12.2; P<0.001). Nigrostriatal iron content decreased more in the deferiprone group than in the placebo group. The main serious adverse events with deferiprone were agranulocytosis in 2 participants and neutropenia in 3 participants. CONCLUSIONS: In participants with early Parkinson's disease who had never received levodopa and in whom treatment with dopaminergic medications was not planned, deferiprone was associated with worse scores in measures of parkinsonism than those with placebo over a period of 36 weeks. (Funded by the European Union Horizon 2020 program; FAIRPARK-II ClinicalTrials.gov number, NCT02655315.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Self-citation(2010) · University of Twente Research Information · Cited by 6,037
The role of iron in brain ageing and neurodegenerative disorders
Ward, R. J., Zucca, F. A., Duyn, J. H., Crichton, R. R., & Zecca, L. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70117-6 · Cited by 1,819
Goetz, C. G., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stebbins, G. T., Stern, M. B., Tilley, B. C., Dodel, R., Dubois, B., et al. (2007) · Movement Disorders · doi:10.1002/mds.21198 · Cited by 1,404
Self-citationJENKINSON, C., FITZPATRICK, R., PETO, V., GREENHALL, R., & HYMAN, N. (1997) · Age and Ageing · doi:10.1093/ageing/26.5.353 · Cited by 1,321
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809335 · Cited by 901
Self-citationDo Van, B., Gouel, F., Jonneaux, A., Timmerman, K., Gelé, P., Pétrault, M., Bastide, M., Laloux, C., Moreau, C., Bordet, R., et al. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.05.011 · Cited by 689
Self-citationTargeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease
Devos, D., Moreau, C., Devedjian, J. C., Kluza, J., Petrault, M., Laloux, C., Jonneaux, A., Ryckewaert, G., Garçon, G., Rouaix, N., et al. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5593 · Cited by 619
Self-citationFerroptosis and its potential role in the physiopathology of Parkinson’s Disease
Mahoney-Sánchez, L., Bouchaoui, H., Ayton, S., Devos, D., Duce, J. A., & Devedjian, J.-C. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101890 · Cited by 553
Self-citationStriking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration
Masaldan, S., Bush, A. I., Devos, D., Rolland, A. S., & Moreau, C. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.09.033 · Cited by 481
Self-citationMartin-Bastida, A., Ward, R. J., Newbould, R., Piccini, P., Sharp, D., Kabba, C., Patel, M. C., Spino, M., Connelly, J., Tricta, F., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01402-2 · Cited by 379
Self-citationThe burden of Parkinson's disease: a worldwide perspective
Rocca, W. A. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30355-7 · Cited by 270
Liu, G. F., Lu, K., Mogg, R., Mallick, M., & Mehrotra, D. V. (2009) · Statistics in Medicine · doi:10.1002/sim.3639 · Cited by 254
Significance levels from repeated p-values with multiply imputed data
Li, K. H., Meng, X., Raghunathan, T. E., & Rubin, D. B. (1991) · Statistica Sinica · Cited by 241
Safety profile of the oral iron chelator deferiprone: a multicentre study
Cohen, Galanello, Piga, DiPalma, Vullo, & Tricta (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.01866.x · Cited by 192
studygroups, T. F.-I. A. F.-I., Devos, D., Cabantchik, Z. I., Moreau, C., Danel-Brunaud, V., Mahoney‐Sanchez, L., Bouchaoui, H., Gouel, F., Rolland, A., Duce, J. A., et al. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-019-02138-1 · Cited by 141
Self-citationIron as a therapeutic target for Parkinson's disease
Moreau, C., Duce, J. A., Rascol, O., Devedjian, J.-C., Berg, D., Dexter, D. T., Cabantchik, Z. I., Bush, A. I., Devos, D., & the FAIRPARK‐II study group (2018) · Movement Disorders · doi:10.1002/mds.27275 · Cited by 137
Self-citationHopes, L., Grolez, G., Moreau, C., Lopes, R., Ryckewaert, G., Carrière, N., Auger, F., Laloux, C., Pétrault, M., Devedjian, J.-C., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147947 · Cited by 96
Self-citationDuce, J. A., Wong, B. X. W., Durham, H., Devedjian, J.-C., Smith, D. P., & Devos, D. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0186-8 · Cited by 85
Self-citationRegional siderosis: a new challenge for iron chelation therapy
Cabantchik, Z. I., Münnich, A., Youdim, M. B. H., & Devos, D. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00167 · Cited by 70
Self-citationMorrish, P. (2003) · Movement Disorders · doi:10.1002/mds.10581 · Cited by 69
Wiesinger, J. A., Buwen, J. P., Cifelli, C. J., Unger, E. L., Jones, B. C., & Beard, J. L. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04175.x · Cited by 42
Crichton, R. R., Ward, R. J., & Hider, R. C. (2019) · Pharmaceuticals · doi:10.3390/ph12030138 · Cited by 38
Cited by
Cascella, M., Montomoli, J., Bellini, V., & Bignami, E. (2023) · Journal of Medical Systems · doi:10.1007/s10916-023-01925-4 · Cited by 1,120
Iron Homeostasis and Ferroptosis in Human Diseases: Mechanisms and Therapeutic Prospects
Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01969-z · Cited by 724
Understanding mechanisms of antioxidant action in health and disease
Halliwell, B. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00645-4 · Cited by 629
Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential
Henrich, M. T., Oertel, W. H., Surmeier, D. J., & Geibl, F. F. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00676-7 · Cited by 406
Ferroptosis in health and disease
Berndt, C., Alborzinia, H., Amen, V. S., Ayton, S., Barayeu, U., Bartelt, A., Bayir, H., Bebber, C. M., Birsoy, K., Böttcher, J. P., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103211 · Cited by 334
Self-citation
Metadata
- Authors
- Devos, D., Labreuche, J., Rascol, O., Corvol, J.-C., Duhamel, A., Guyon Delannoy, P., Poewe, W., Compta, Y., Pavese, N., Růžička, E., Dušek, P., Post, B., Bloem, B. R., Berg, D., Maetzler, W., Otto, M., Habert, M.-O., Lehericy, S., Ferreira, J., Dodel, R., Tranchant, C., Eusebio, A., Thobois, S., Marques, A.-R., Meissner, W. G., Ory-Magne, F., Walter, U., de Bie, R. M. A., Gago, M., Vilas, D., Kulisevsky, J., Januario, C., Coelho, M. V. S., Behnke, S., Worth, P., Seppi, K., Ouk, T., Potey, C., Leclercq, C., Viard, R., Kuchcinski, G., Lopes, R., Pruvo, J.-P., Pigny, P., Garçon, G., Simonin, O., Carpentier, J., Rolland, A.-S., Nyholm, D., Scherfler, C., Mangin, J.-F., Chupin, M., Bordet, R., Dexter, D. T., Fradette, C., Spino, M., Tricta, F., Ayton, S., Bush, A. I., Devedjian, J.-C., Duce, J. A., Cabantchik, I., Defebvre, L., Deplanque, D., & Moreau, C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-12
- Volume
- 387
- Issue
- 22
- Pages
- 2045-2055
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4311024711
- Cited by
- 254
- References
- 25
- FWCI
- 21.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.